文献速递眼底病与葡萄膜炎

抗VEGF时代年龄相关性黄斑变性相关视乳头旁脉络膜新生血管的特征

AGE-RELATED MACULAR DEGENERATION-ASSOCIATED PERIPAPILLARY CHOROIDAL NEOVASCULARIZATION IN THE ERA OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
PubMed 文献 · Retina · 2019-01-01

结果显示部分无黄斑积液眼可长期保持干燥,出现积液者抗VEGF治疗后液体吸收快、视力结局良好,但液体复发中位时间6个月。

要点

  • 24眼中10眼(42%)初始无黄斑积液者整个随访期间保持干燥。
  • 首个治疗周期液体完全吸收所需中位注射次数为3次,液体复发中位时间6个月。

核心结论

  • 继发于湿性年龄相关性黄斑变性的视乳头旁脉络膜新生血管进展缓慢,可能长期无需治疗,对抗VEGF治疗反应迅速且视力结局良好。

研究设计与样本

  • 对有视网膜下或视网膜内黄斑积液的眼采用抗VEGF单药治疗,使用改良的按需治疗方案。

主要发现

  • 中位年龄82岁(范围62-94),中位随访时间65个月(范围6-165)。
  • 初始无黄斑积液的24眼中10眼(42%)整个随访期间保持干燥。
  • 首个治疗周期液体完全吸收所需中位注射次数为3次(范围1-21),液体复发中位时间为6个月(范围3-74)。

临床怎么用

  • 对继发于湿性年龄相关性黄斑变性的视乳头旁脉络膜新生血管,可考虑采用改良按需抗VEGF治疗方案,但需长期随访监测渗出出现或复发。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To characterize the natural history and response of age-related macular degeneration-associated peripapillary choroidal neovascularization to anti-vascular endothelial growth factor therapy. METHODS: This was a retrospective case series of patients with peripapillary choroidal neovascularization secondary to neovascular age-related macular degeneration. All patients underwent complete ophthalmologic examination and retinal imaging including fluorescein angiography and spectral domain optical coherence tomography at each visit. Eyes with subretinal or intraretinal macular fluid were treated with anti-vascular endothelial growth factor monotherapy using a modified as-needed treatment algorithm. RESULTS: Thirty-three eyes of 27 patients were included. The median age was 82 years (range, 62-94), and the median duration of follow-up was 65 months (range, 6-165). Fourteen eyes (58%) without fovea-involving fluid at baseline subsequently developed exudation after a median observation period of 16 months (range, 4-107). Ten of 24 eyes (42%) without initial macular fluid remained dry during the entire follow-up. The median number of injections required until complete fluid reabsorption was 3 (range, 1-21) during the first treatment cycle. The median time to fluid recurrence was 6 months (range, 3-74). CONCLUSION: Peripapillary choroidal neovascularization secondary to wet age-related macular degeneration has a slow progression, may not require treatment for a prolonged period, and responds rapidly to anti-vascular endothelial growth factor treatment with good visual outcomes.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Lin T, Dans K, Meshi A, et al. AGE-RELATED MACULAR DEGENERATION-ASSOCIATED PERIPAPILLARY CHOROIDAL NEOVASCULARIZATION IN THE ERA OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY. Retina. 2019. PMID: 30028411. doi:10.1097/IAE.0000000000002272

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。